PriceTargets.com logo

Palisade Bio - PALI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.50
  • Forecasted Upside: 526.74%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.59 As of 09/6/2024 01:00 AM ET
▼ -0.08 (-2.18%)

This chart shows the closing price for PALI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palisade Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PALI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PALI

Analyst Price Target is $22.50
▲ +526.74% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $22.50, with a high forecast of $22.50 and a low forecast of $22.50. The average price target represents a 526.74% upside from the last price of $3.59.

This chart shows the closing price for PALI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Palisade Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2024Maxim GroupReiterated RatingBuy ➝ Buy$22.50Low
4/16/2024Maxim GroupReiterated RatingBuy ➝ Buy$22.50Low
11/17/2023Maxim GroupUpgradeHold ➝ Buy$22.50Low
8/9/2023Maxim GroupDowngradeBuy ➝ HoldLow
5/16/2023LADENBURG THALM/SH SHLower Target$375.00 ➝ $240.00Low
3/30/2023Maxim GroupUpgradeHold ➝ BuyLow
8/19/2022Maxim GroupDowngradeBuy ➝ HoldLow
2/2/2022LADENBURG THALM/SH SHInitiated CoverageBuy$75.00High
8/31/2021Maxim GroupInitiated CoverageBuy$105.00High
(Data available from 9/8/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/11/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2024
  • 4 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More

Today's Range

Now: $3.59
Low: $3.42
High: $3.67

50 Day Range

MA: $3.92
Low: $3.43
High: $4.54

52 Week Range

Now: $3.59
Low: $3.30
High: $22.35

Volume

5,570 shs

Average Volume

498,019 shs

Market Capitalization

$3.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Palisade Bio?

The following Wall Street analysts have issued reports on Palisade Bio in the last year: Maxim Group.
View the latest analyst ratings for PALI.

What is the current price target for Palisade Bio?

1 Wall Street analysts have set twelve-month price targets for Palisade Bio in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 526.7%. Maxim Group has the highest price target set, predicting PALI will reach $22.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $22.50 for Palisade Bio in the next year.
View the latest price targets for PALI.

What is the current consensus analyst rating for Palisade Bio?

Palisade Bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PALI will outperform the market and that investors should add to their positions of Palisade Bio.
View the latest ratings for PALI.

What other companies compete with Palisade Bio?

Other companies that are similar to Palisade Bio include Plus Therapeutics, Trinity Biotech, Indaptus Therapeutics, Flora Growth and Longeveron. Learn More about companies similar to Palisade Bio.

How do I contact Palisade Bio's investor relations team?

Palisade Bio's physical mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company's listed phone number is (858) 704-4900 and its investor relations email address is [email protected]. The official website for Palisade Bio is www.palisadebio.com. Learn More about contacing Palisade Bio investor relations.